← All trials
NCT05724134
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2023
- Primary completion
- Aug 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Feb 13, 2023
- Last posted
- Nov 2, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- Columbia UniversityOverall official - principal investigator
- Columbia UniversityReponsible party - principal investigator
- Yeshiva UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.